S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Low VIX? 3 High Beta Stocks To Boost Your Returns
Best Bear Market Funds: Top 3 Investment Options to Consider
How and When to Roll Your Options Positions?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Low VIX? 3 High Beta Stocks To Boost Your Returns
Best Bear Market Funds: Top 3 Investment Options to Consider
How and When to Roll Your Options Positions?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Low VIX? 3 High Beta Stocks To Boost Your Returns
Best Bear Market Funds: Top 3 Investment Options to Consider
How and When to Roll Your Options Positions?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Low VIX? 3 High Beta Stocks To Boost Your Returns
Best Bear Market Funds: Top 3 Investment Options to Consider
How and When to Roll Your Options Positions?
NASDAQ:BNR

Burning Rock Biotech (BNR) Stock Price, News & Analysis

$0.70
0.00 (0.00%)
(As of 03/27/2024 ET)
Today's Range
$0.66
$0.75
50-Day Range
$0.68
$0.97
52-Week Range
$0.57
$3.25
Volume
102,209 shs
Average Volume
59,560 shs
Market Capitalization
$71.85 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
BNR stock logo

About Burning Rock Biotech Stock (NASDAQ:BNR)

Burning Rock Biotech Limited primarily develops and commercializes cancer therapy selection tests in the People's Republic of China. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company primarily offers next-generation sequencing-based tissue and liquid biopsy cancer therapy selection and prognosis prediction tests for various range of cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples. Its principal products include OncoCompass IO, a corresponding test for liquid biopsy samples; OncoScreen IO, a pan-cancer test for tissue samples; and OncoCompass Target, a ctDNA liquid biopsy-based test for NSCLC. In addition, the company provides ColonCore for assessing microsatellite loci related to MSI status and detecting mutations in genes associated with gastrointestinal cancers; and brPROPHET, a pre-operative ctDNA detection and post-operative MRD calling for relapsed patients. Further, it has development and commercialization agreement with Myriad Genetics, Inc. to in-license Myriad myChoice tumor testing in China; licensing agreement with Oncocyte Corporation to in-license DetermaRx, a risk stratification test for early stage lung cancer patients in China; and collaborations on clinical trials and research studies with AstraZeneca, Bayer, Johnson & Johnson, CStone, BeiGene, Abbisko Therapeutics, and IMPACT Therapeutics and Merck KGaA. Additionally, the company offers OncoMaster, an automatic NGS data analysis and report interpretation machine for in-hospital model. Burning Rock Biotech Limited was incorporated in 2014 and is headquartered in Guangzhou, China.

BNR Stock Price History

BNR Stock News Headlines

Burning Rock Biotech (NASDAQ:BNR) Trading Down 8.5%
Burning Rock Biotech Ltd. ADR
SHOCKING Crypto Leak…
A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.
Burning Rock Biotech Ltd (BNR)
the most reliable asset on earth is making a comeback
Global tensions have been pushing the price of gold to all time highs… Just recently, gold peaked at a record $2,000 (and is now closer to $2,200). And there’s something else critical at play right now in the world’s largest asset. Because of these critical factors, a lot of massive investment institutions are now pumping more money into gold. And as we speak, some are even calling for a massive rally in the precious metal.
Burning Rock Biotech Ltd ADR
Q3 2023 Burning Rock Biotech Ltd Earnings Call
Burning Rock Reports Third Quarter 2023 Financial Results
Q2 2023 Burning Rock Biotech Ltd Earnings Call
Burning Rock Biotech Q2 Loss Narrows
See More Headlines
Receive BNR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Burning Rock Biotech and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/16/2021
Today
3/28/2024
Next Earnings (Estimated)
5/28/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Industry
Medical laboratories
Sub-Industry
N/A
Current Symbol
NASDAQ:BNR
Fax
N/A
Employees
1,138
Year Founded
N/A

Profitability

Net Income
$-140,820,000.00
Net Margins
-127.05%
Pretax Margin
-122.10%

Debt

Sales & Book Value

Annual Sales
$81.66 million
Book Value
$1.64 per share

Miscellaneous

Free Float
71,542,000
Market Cap
$71.85 million
Optionable
Not Optionable
Beta
0.25
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

BNR Stock Analysis - Frequently Asked Questions

How have BNR shares performed in 2024?

Burning Rock Biotech's stock was trading at $0.93 at the start of the year. Since then, BNR shares have decreased by 24.7% and is now trading at $0.70.
View the best growth stocks for 2024 here
.

When is Burning Rock Biotech's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 28th 2024.
View our BNR earnings forecast
.

How were Burning Rock Biotech's earnings last quarter?

Burning Rock Biotech Limited (NASDAQ:BNR) posted its quarterly earnings data on Tuesday, November, 16th. The company reported ($1.64) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.61) by $0.03. The company had revenue of $19.65 million for the quarter. Burning Rock Biotech had a negative trailing twelve-month return on equity of 70.22% and a negative net margin of 127.05%. During the same period in the previous year, the company posted ($0.18) EPS.

What other stocks do shareholders of Burning Rock Biotech own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Burning Rock Biotech investors own include Tiziana Life Sciences (TLSA), Teck Resources (TECK), Herman Miller (MLHR) and Immunic (IMUX).

When did Burning Rock Biotech IPO?

Burning Rock Biotech (BNR) raised $196 million in an initial public offering on Friday, June 12th 2020. The company issued 13,500,000 shares at $13.50-$15.50 per share. Morgan Stanley, BofA Securities and Cowen acted as the underwriters for the IPO and CMBI and Tiger Brokers were co-managers.

Who are Burning Rock Biotech's major shareholders?

Burning Rock Biotech's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Kynam Capital Management LP (8.47%), Massachusetts Financial Services Co. MA (3.94%) and Redwood Wealth Management Group LLC (0.11%).

How do I buy shares of Burning Rock Biotech?

Shares of BNR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:BNR) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners